Project Grant R03OD038391
Award Date
9/5/24
Completion Date
9/4/25
Dollars Obligated
$307K
Funding Federal Agency
Office of the Director
Awarding Federal Agency
Aggregate Financial Assistance Data
Federal Grant Program
93.310
Assistance Type
Project Grant
Place of Performance
Omaha, NE 68198, USA
Similar Awards
This $627,833 federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) aims to develop an informatics platform that integrates molecular and pathological data from various lung cancer preclinical models and patient tumors. The goal is to assess the fidelity of these preclinical models through comparative analyses. The University of Texas Southwestern Medical Center, the prime awardee, will work with Duke University as a sub-awardee to...
This $1,480,500 federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) aims to elucidate the cell intrinsic and extrinsic mechanisms underlying small cell lung cancer (SCLC) metastasis. The project will develop cutting-edge technologies to establish a comprehensive, spatiotemporally-resolved lineage tracing platform capable of recording the entire course of SCLC metastasis. Specifically, the...
The National Cancer Institute (NCI) awarded a $256,487 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Sloan-Kettering Institute for Cancer Research in New York, NY. The purpose of this 5-year grant is to develop multimodal predictive models that integrate real-world data from circulating tumor DNA (ctDNA) sequencing, radiomics, tumor registries, and tissue genomics to improve risk stratification and clinical management of non-small cell lung cancer (NSCLC). The...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $1,625,000.00 to Onc.ai, Inc. to develop and validate a radiomics-based multi-modal predictive model for metastatic non-small cell lung cancer patients treated with PD-1 immunotherapy. The key objectives are to: 1) Validate the predictive models in a multi-institutional prospective clinical study, 2) Evaluate the performance characteristics and...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $1,999,108 to Orbit Genomics, Inc. to develop a high sensitivity, high specificity diagnostic test for lung cancer subtyping. The goal is to create a test that can distinguish between different lung cancer subtypes, which is critical for selecting the most effective treatment and reducing mortality. The project involves obtaining subtype training samples, upgrading...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $230,010 to the University of Chicago to conduct research aimed at unraveling the mechanisms driving metastasis in small cell lung cancer (SCLC). The research strategy integrates human pluripotent stem cell-derived SCLC models, clinical samples, patient-derived xenografts, and advanced technologies like single-cell sequencing to investigate the cellular and molecular...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $701,538 to the Icahn School of Medicine at Mount Sinai to investigate the lineage evolution and epigenomic signatures of a distinct subtype of small cell lung cancer (SCLC) characterized by the lineage factor NKX2-1. The research aims to: 1) Determine how cell-of-origin and NKX2-1 impact the evolution and maintenance of this SCLC epigenomic subtype, 2) Elucidate the...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $968,999.00 to the University of North Carolina at Chapel Hill to conduct research titled "OPTIMIZING SURVEILLANCE IN LUNG CANCER SURVIVORS WITH NOVEL IMAGING BIOMARKERS AND DEEP-LEARNING (OPTIMAL)". The overarching goal is to optimize survivorship of early-stage non-small cell lung cancer patients by incorporating a risk-based surveillance strategy that...
This $160,330 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports the development of novel human-relevant lung adenocarcinoma models at the University of Illinois. The goal is to create organoid and xenograft models by genome editing primary human lung stem and progenitor cells to better capture the initiation, progression, and composition of primary human lung tumors compared to current mouse models. The research aims to characterize...
This federal Project Grant award of $505,613 from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) will fund the development of statistical and computational approaches to leverage genomic data for precision cancer prevention. The key products and services to be delivered include: Deep learning-based methods to identify tumor heterogeneity and predictive biomarkers of aggressive cancer, integrating spatial omics data. Statistical...